Modification of the Incidence of Drug-Associated Symmetrical Peripheral Neuropathy by Host and Disease Factors in the HIV Outpatient Study Cohort
Open Access
- 1 January 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (1), 148-157
- https://doi.org/10.1086/426076
Abstract
Background. We sought to identify factors associated with the clinical diagnosis of symmetrical peripheral neuropathy (SPN) during the era of highly active antiretroviral therapy (HAART) in a retrospective, longitudinal cohort analysis. Methods. Patients infected with human immunodeficiency virus type 1 were evaluated for clinical signs of SPN and its association with immunologic, virologic, clinical, and drug treatment factors by means of univariate and multivariate logistic regression analyses. Results. Of 2515 patients, 329 (13.1%) received a diagnosis of SPN. In the logistic regression analysis, statistically significant non—drug-based risk factors for SPN were age >40 years (adjusted odds ratio [aOR], 1.17), diabetes mellitus (aOR, 1.79), white race (aOR, 1.33), nadir CD4+ T lymphocyte count 10,000 copies/mL at first measurement (aOR, 1.44). Although initial use of didanosine, stavudine (40 mg b.i.d.), nevirapine, or 4 protease inhibitors was associated with SPN (ORs for all 4 treatments, >1.41), the strength of association decreased with continued use of all medications studied. Conclusion. Since HAART was introduced, the incidence of SPN has decreased. Host factors and signs of increased disease severity were associated with an increased risk of developing SPN during the initial period of exposure to drug therapy. Immunity improved and the risk of SPN decreased with continued use of HAART. Delaying the initiation of therapy may select those individuals who will be more likely to develop SPN, and earlier initiation of HAART may decrease the risk of developing this common problem, as well as increase the therapeutic effects and decrease the toxic effects of the drugs.Keywords
This publication has 29 references indexed in Scilit:
- The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical ToxicitiesClinical Infectious Diseases, 2004
- Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsAIDS, 2003
- Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicityClinical Therapeutics, 2000
- Neuromuscular function in HIV infectionAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Peripheral Neuropathy with Nucleoside AntiretroviralsDrug Safety, 1998
- Human immunodeficiency virus infection of dorsal root ganglion neurons detected by polymerase chain reaction in situ hybridizationAnnals of Neurology, 1997
- Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cellsJournal of the Neurological Sciences, 1997
- Low-dose zalcitabine-related toxic neuropathyNeurology, 1996
- Increased NADPH-diaphorase reactivity and cytokine expression in dorsal root ganglia in acquired immunodeficiency syndromeJournal of the Neurological Sciences, 1996